JP2004507519A5 - - Google Patents

Download PDF

Info

Publication number
JP2004507519A5
JP2004507519A5 JP2002523438A JP2002523438A JP2004507519A5 JP 2004507519 A5 JP2004507519 A5 JP 2004507519A5 JP 2002523438 A JP2002523438 A JP 2002523438A JP 2002523438 A JP2002523438 A JP 2002523438A JP 2004507519 A5 JP2004507519 A5 JP 2004507519A5
Authority
JP
Japan
Prior art keywords
group
compound
formula
atom
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002523438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507519A (ja
JP3899022B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/026594 external-priority patent/WO2002018320A2/en
Publication of JP2004507519A publication Critical patent/JP2004507519A/ja
Publication of JP2004507519A5 publication Critical patent/JP2004507519A5/ja
Application granted granted Critical
Publication of JP3899022B2 publication Critical patent/JP3899022B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002523438A 2000-08-31 2001-08-27 α4介在細胞接着阻害剤 Expired - Fee Related JP3899022B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22912800P 2000-08-31 2000-08-31
PCT/US2001/026594 WO2002018320A2 (en) 2000-08-31 2001-08-27 INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (3)

Publication Number Publication Date
JP2004507519A JP2004507519A (ja) 2004-03-11
JP2004507519A5 true JP2004507519A5 (cg-RX-API-DMAC7.html) 2005-02-24
JP3899022B2 JP3899022B2 (ja) 2007-03-28

Family

ID=22859926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523438A Expired - Fee Related JP3899022B2 (ja) 2000-08-31 2001-08-27 α4介在細胞接着阻害剤

Country Status (28)

Country Link
US (6) US7026501B2 (cg-RX-API-DMAC7.html)
EP (1) EP1315694B1 (cg-RX-API-DMAC7.html)
JP (1) JP3899022B2 (cg-RX-API-DMAC7.html)
KR (1) KR100528049B1 (cg-RX-API-DMAC7.html)
CN (1) CN1229334C (cg-RX-API-DMAC7.html)
AR (1) AR034556A1 (cg-RX-API-DMAC7.html)
AT (1) ATE292615T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001286778B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113629A (cg-RX-API-DMAC7.html)
CA (1) CA2418054C (cg-RX-API-DMAC7.html)
CZ (1) CZ303460B6 (cg-RX-API-DMAC7.html)
DE (1) DE60109943T2 (cg-RX-API-DMAC7.html)
DK (1) DK1315694T3 (cg-RX-API-DMAC7.html)
ES (1) ES2240509T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052684B (cg-RX-API-DMAC7.html)
HU (1) HUP0302693A3 (cg-RX-API-DMAC7.html)
IL (2) IL154305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001837A (cg-RX-API-DMAC7.html)
MY (1) MY129000A (cg-RX-API-DMAC7.html)
NO (1) NO327861B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524043A (cg-RX-API-DMAC7.html)
PL (1) PL206656B1 (cg-RX-API-DMAC7.html)
PT (1) PT1315694E (cg-RX-API-DMAC7.html)
RU (1) RU2250895C2 (cg-RX-API-DMAC7.html)
SI (1) SI1315694T1 (cg-RX-API-DMAC7.html)
TW (1) TWI224587B (cg-RX-API-DMAC7.html)
WO (1) WO2002018320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301039B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302653B6 (cs) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Fenylalaninové deriváty, alfa-4-integrinový antagonist, terapeutické cinidlo nebo preventivní cinidlo a farmaceutický prostredek obsahující tyto deriváty
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
KR100881647B1 (ko) 2001-04-27 2009-02-04 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로[1,5-a]피리딘 화합물 및 그 의약
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
PT1555265E (pt) * 2002-10-22 2009-05-12 Eisai R&D Man Co Ltd Compostos de 7-fenil pirazolopiridina
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
ZA200605587B (en) 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
US7410971B2 (en) 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
JP4966017B2 (ja) 2004-12-20 2012-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 1−シクロプロピルメチル−4−[2−(3,3,5,5−テトラメチルシクロヘキシル)フェニル]ピペラジンの塩および結晶
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム 2,6キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
EP2091916A2 (en) * 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
EP1984344B1 (en) * 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP1984330A1 (en) * 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
EP2676967B1 (en) 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
JP5553752B2 (ja) * 2007-08-24 2014-07-16 レクシコン ファーマシューティカルズ インコーポレイテッド 4−フェニル−6−(2,2,2−トリフルオロ−1−フェニルエトキシ)ピリミジン系化合物を調製する方法
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CA2777158A1 (en) 2009-10-21 2011-04-28 Joseph Paul Adams Process for preparing a phenylalanine derivative
SG181653A1 (en) 2010-01-11 2012-07-30 Biogen Idec Inc Assay for jc virus antibodies
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2715352T (pt) 2011-05-31 2019-06-12 Biogen Ma Inc Método de avaliação do risco de lmp
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
EP0728145A1 (en) 1993-11-01 1996-08-28 Ciba-Geigy Japan Limited Endothelin receptor antagonists
BR9507220A (pt) 1994-03-28 1997-09-09 Japat Ltd Antagonistas de receptores de endotelina
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
JP2002501537A (ja) 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのスルホンアミド類
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
ATE256699T1 (de) 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate
WO1998058902A1 (en) 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
AU8661298A (en) 1997-07-31 1999-02-22 American Home Products Corporation Dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1133648C (zh) 1997-07-31 2004-01-07 伊兰药品公司 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
KR20010022414A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Vla-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
HUP0003921A3 (en) 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
JP2001512135A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4によって媒介された白血球接着を阻害するジペプチドおよび関連化合物
IL133635A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
JP2001512136A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4により仲介される白血球接着を抑制する化合物
ATE260243T1 (de) 1997-08-22 2004-03-15 Hoffmann La Roche N-aroylphenylalaninderivate
AU739511B2 (en) * 1997-08-22 2001-10-11 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
JP2001524465A (ja) 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
JP2001523711A (ja) 1997-11-24 2001-11-27 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害薬としての環状アミノ酸誘導体
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
ES2220140T3 (es) 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1214292B1 (en) * 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
US20040198833A1 (en) 2000-08-31 2004-10-07 Bender David Michael Acetylenic sulfonamide derivatives

Similar Documents

Publication Publication Date Title
JP2004507519A5 (cg-RX-API-DMAC7.html)
JP2009533369A5 (cg-RX-API-DMAC7.html)
JP2005526011A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
JP2001261662A5 (cg-RX-API-DMAC7.html)
JP2005517666A5 (cg-RX-API-DMAC7.html)
JP2005533789A5 (cg-RX-API-DMAC7.html)
JP2007500753A5 (cg-RX-API-DMAC7.html)
JP2007510619A5 (cg-RX-API-DMAC7.html)
JP2007501809A5 (cg-RX-API-DMAC7.html)
JP2006514626A5 (cg-RX-API-DMAC7.html)
JP2010521514A5 (cg-RX-API-DMAC7.html)
JPH10279578A5 (cg-RX-API-DMAC7.html)
JP2005511697A5 (cg-RX-API-DMAC7.html)
JPH1077292A5 (cg-RX-API-DMAC7.html)
RU2010131010A (ru) Способ получения 6-замещенных-1-(2н)-изохинолинонов
JP2004506769A5 (cg-RX-API-DMAC7.html)
JP2005502636A5 (cg-RX-API-DMAC7.html)
JP2005502603A5 (cg-RX-API-DMAC7.html)
JP2003012683A5 (cg-RX-API-DMAC7.html)
JPH1112272A5 (cg-RX-API-DMAC7.html)
JP2005154442A5 (cg-RX-API-DMAC7.html)
JP2002519409A5 (cg-RX-API-DMAC7.html)
JP2002121189A5 (cg-RX-API-DMAC7.html)
JP2005513126A5 (cg-RX-API-DMAC7.html)